Advertisement
Screener

Ovid Therapeutics Inc. (OVID) Net Cash Provided by (Used in) Investing Activities, Continuing Operations

1.9 / 5 stars · 25/65 Roast Me

Ovid Therapeutics Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations

Ovid Therapeutics Inc. (OVID) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$45.07 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.

Discontinued › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-08

  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$45.07M.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $61.71K.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$25.33K.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$31.19K.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$47.39K.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$188.99K.
  • Ovid Therapeutics Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$56.33K.
Period endNet Cash Provided by (Used in) Investing Activities, Continuing Operations 3 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 6 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 9 monthNet Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month
2018-03-31-$45.07M
10-Q · filed 2018-05-08
-$45.01M
derived: sum of 2 quarters · filed 2018-05-08
-$45.04M
derived: sum of 3 quarters · filed 2018-05-08
-$45.07M
derived: sum of 4 quarters · filed 2018-05-08
2017-12-31$61.71K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29
$36.38K
derived: sum of 2 quarters · filed 2018-03-29
$5.18K
derived: sum of 3 quarters · filed 2018-03-29
-$47.39K
10-K · filed 2018-03-29
2017-09-30-$25.33K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
-$56.52K
derived: sum of 2 quarters · filed 2017-11-09
-$109.09K
10-Q · filed 2017-11-09
-$197.19K
derived: sum of 4 quarters · filed 2018-05-08
2017-06-30-$31.19K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10
-$83.76K
10-Q · filed 2017-08-10
-$171.86K
derived: sum of 3 quarters · filed 2018-05-08
-$237.30K
derived: sum of 4 quarters · filed 2018-05-08
2017-03-31-$52.57K
10-Q · filed 2018-05-08
-$140.66K
derived: sum of 2 quarters · filed 2018-05-08
-$206.11K
derived: sum of 3 quarters · filed 2018-05-08
-$213.40K
derived: sum of 4 quarters · filed 2018-05-08
2016-12-31-$88.09K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29
-$153.54K
derived: sum of 2 quarters · filed 2018-03-29
-$160.83K
derived: sum of 3 quarters · filed 2018-03-29
-$188.99K
10-K · filed 2018-03-29
2016-09-30-$65.44K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
-$72.74K
derived: sum of 2 quarters · filed 2017-11-09
-$100.89K
10-Q · filed 2017-11-09
2016-06-30-$7.30K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10
-$35.45K
10-Q · filed 2017-08-10
2016-03-31-$28.15K
10-Q · filed 2017-06-13
2015-12-31-$56.33K
10-K · filed 2018-03-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
ASSEMBLY BIOSCIENCES, INC. (ASMB)United States$0.481B-13,053.96
CAPRICOR THERAPEUTICS, INC. (CAPR)United States$0.499B-10.81
PUMA BIOTECHNOLOGY, INC. (PBYI)United States$0.507B15.53
ARVINAS, INC. (ARVN)United States$0.510B58.38
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Evolus, Inc. (EOLS)United States$0.519B-13.32
CRESCENT BIOPHARMA, INC. (CBIO)United States$0.529B-5.20
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63
Indaptus Therapeutics, Inc. (INDP)United States$0.537B